Gene Therapy Ophthalmology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2017
This report can be delivered to the clients within 24 Hours
DelveInsight’s report, “Gene Therapy Ophthalmology Insight - Pipeline Assessment, Market Trend, Technology and Competitive Landscape, 2017” emphasizes on the currently under development Gene Therapy products in Opthalmology.
The report covers 15+ companies, which are active in this field with 42 products and various technologies. This report includes: Gene Therapy products in Ophthalmology by companies and Research Activities by Institutes in this area. The report provides in-depth analysis of the product profiles covering their pre-clinical and clinical studies, collaboration details and deal values, technologies and targeted indications. The report further gives information on market drivers and barriers followed by the SWOT Analysis.
SCOPE
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and access to available databases.
DelveInsight’s report, “Gene Therapy Ophthalmology Insight - Pipeline Assessment, Market Trend, Technology and Competitive Landscape, 2017” emphasizes on the currently under development Gene Therapy products in Opthalmology.
The report covers 15+ companies, which are active in this field with 42 products and various technologies. This report includes: Gene Therapy products in Ophthalmology by companies and Research Activities by Institutes in this area. The report provides in-depth analysis of the product profiles covering their pre-clinical and clinical studies, collaboration details and deal values, technologies and targeted indications. The report further gives information on market drivers and barriers followed by the SWOT Analysis.
SCOPE
- Overview of the Gene Therapy products in Ophthalmology
- Pipeline scenario of Gene Therapy products in Ophthalmology under development different companies and research institutes
- Competitive landscape of products
- Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles including: mechanism of action, route of administration and molecule type along with product development activities
- Coverage of licensors, collaborators and development partners, deal terms and deal values
- Highlights of latest developmental technologies for Gene Therapy products in Ophthalmology
- Market drivers and barriers along with the SWOT analysis
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and access to available databases.
Report Introduction
Executive Summary
Overview
Gene Therapy and Ophthalmology
Gene Transfer Systems
Adenovirus: An Efficient Vector
Competitive Landscape
Collaborations and Deal values
Designation Analysis
Developmental Technologies
Gene Therapy products in Ophthalmology on the basis of Delivery System
Gene Therapy Products in Ophthalmology by Indication
Pipeline Therapeutics (Company Sponsored)
Comparative Analysis
Late Stage Products (Filed and Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Candidate Profiles
SAR 421869: Sanofi
Product Description
Research and Development
Product Development Activities
NSR AAV-RPGR: NightstaRx Limited
Product Description
Research and Development
Product Development Activities
Therapeutic Assessment: Active Products (Company Sponsored)
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Stage and Molecule Type
Discontinued Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Dormant Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Research Activities by Institutions
Drug Name: Institute Name
Product Description
Research and Development
Product Development Activities
Market Barriers and Drivers
Drivers
Barriers
SWOT Analysis
Appendix
Methodology
Consulting Services
Disclaimer
Report Purchase Options
About DelveInsight
Executive Summary
Overview
Gene Therapy and Ophthalmology
Gene Transfer Systems
Adenovirus: An Efficient Vector
Competitive Landscape
Collaborations and Deal values
Designation Analysis
Developmental Technologies
Gene Therapy products in Ophthalmology on the basis of Delivery System
Gene Therapy Products in Ophthalmology by Indication
Pipeline Therapeutics (Company Sponsored)
Comparative Analysis
Late Stage Products (Filed and Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Candidate Profiles
SAR 421869: Sanofi
Product Description
Research and Development
Product Development Activities
NSR AAV-RPGR: NightstaRx Limited
Product Description
Research and Development
Product Development Activities
Therapeutic Assessment: Active Products (Company Sponsored)
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Stage and Molecule Type
Discontinued Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Dormant Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Research Activities by Institutions
Drug Name: Institute Name
Product Description
Research and Development
Product Development Activities
Market Barriers and Drivers
Drivers
Barriers
SWOT Analysis
Appendix
Methodology
Consulting Services
Disclaimer
Report Purchase Options
About DelveInsight
LIST OF TABLES
Table 1: Characteristic features of gene transfer viral vectors
Table 2: Collaboration and Deal Values for Gene Therapies in Ophthalmology
Table 3: Designation Analysis for Gene Therapies in Ophthalmology
Table 4: Companies and their Technologies for Gene Therapies in Ophthalmology
Table 5: Gene Therapy products in Ophthalmology on the basis of Delivery System
Table 6: Gene Therapy Products in Ophthalmology by Indication
Table 7: Total Products for Gene Therapy Ophthalmology
Table 8: Late Stage Products (Filed and Phase III)
Table 9: Mid Stage Products (Phase II)
Table 10: Early Stage Products (Phase I and IND)
Table 11: Pre-clinical and Discovery Stage Products
Table 12: Assessment by Monotherapy Products
Table 13: Assessment by Route of Administration
Table 14: Assessment by Stage and Route of Administration
Table 15: Assessment by Stage and Molecule Type
Table 16: Discontinued Products
Table 17: Dormant Products
Table 1: Characteristic features of gene transfer viral vectors
Table 2: Collaboration and Deal Values for Gene Therapies in Ophthalmology
Table 3: Designation Analysis for Gene Therapies in Ophthalmology
Table 4: Companies and their Technologies for Gene Therapies in Ophthalmology
Table 5: Gene Therapy products in Ophthalmology on the basis of Delivery System
Table 6: Gene Therapy Products in Ophthalmology by Indication
Table 7: Total Products for Gene Therapy Ophthalmology
Table 8: Late Stage Products (Filed and Phase III)
Table 9: Mid Stage Products (Phase II)
Table 10: Early Stage Products (Phase I and IND)
Table 11: Pre-clinical and Discovery Stage Products
Table 12: Assessment by Monotherapy Products
Table 13: Assessment by Route of Administration
Table 14: Assessment by Stage and Route of Administration
Table 15: Assessment by Stage and Molecule Type
Table 16: Discontinued Products
Table 17: Dormant Products
LIST OF FIGURES
Figure 1: Gene Therapy Administration in Ophthalmology
Figure 2: Designation Analysis for Gene Therapies in Ophthalmology
Figure 3: Gene Therapy products in Ophthalmology on the basis of Delivery System
Figure 4: Total Products for Gene Therapy Ophthalmology
Figure 5: Late Stage Products (Filed and Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Stage and Molecule Type
Figure 13: Discontinued Products
Figure 14: Dormant Products
Figure 1: Gene Therapy Administration in Ophthalmology
Figure 2: Designation Analysis for Gene Therapies in Ophthalmology
Figure 3: Gene Therapy products in Ophthalmology on the basis of Delivery System
Figure 4: Total Products for Gene Therapy Ophthalmology
Figure 5: Late Stage Products (Filed and Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Stage and Molecule Type
Figure 13: Discontinued Products
Figure 14: Dormant Products
